Zerbo Ousseny, Modaressi Sharareh, Goddard Kristin, Lewis Edwin, Bok Karin, Gans Hayley, Klein Nicola P
Division of Research, Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA.
US Department of Health and Human Services, National Vaccine Program Office, Office of the Assistant Secretary for Health, Washington, DC, USA.
Hum Vaccin Immunother. 2020 Apr 2;16(4):875-880. doi: 10.1080/21645515.2019.1675458. Epub 2019 Nov 8.
We evaluated whether parental clinical conditions were associated with fever after a first dose of measles-containing vaccine (MCV) in the child in a cohort study including 244,125 children born in Kaiser Permanente Northern California between 2009 and 2016 who received MCV between ages 1 and 2 years. Each child was linked with his/her mother and father when possible. Parental clinical conditions present before and after their child's birth were identified. We defined fever in the children as clinic and emergency department visits with a fever code 7-10 days after a first dose of MCV ("MCV-associated fever"). We evaluated parental clinical conditions associated with MCV-associated fever using multivariate logistic regression analyses. After adjusting for multiple factors, including healthcare utilization, maternal fever [odds ratio (OR) = 1.19, 95% confidence interval (CI) 1.06-1.32], fever after MCV (OR = 5.90, 95% CI 1.35-25.78), respiratory infections (OR = 1.20, 95% CI 1.10-1.31), migraine (OR = 1.14, 95% CI 1.05-1.24), syncope (OR 1.14, 95% CI 1.01-1.27), and essential thrombocythemia (OR = 1.93, 95% CI 1.15-3.25) were significantly associated with MCV-associated fever. Paternal respiratory infections (OR = 1.15, 95% CI 1.05-1.27), fever associated with respiratory infections (OR = 1.47, 95% CI 1.23-1.76), and vitiligo (OR = 1.63, 95% CI 1.06-2.53) were significantly associated with MCV-associated fever. Parental clinical conditions, specifically fever alone and fever associated with respiratory infection, are associated with fever in their child 7-10 days after MCV.
在一项队列研究中,我们评估了父母的临床状况是否与孩子接种第一剂含麻疹疫苗(MCV)后的发热有关。该研究纳入了2009年至2016年在北加利福尼亚凯撒医疗集团出生、1至2岁时接种了MCV的244,125名儿童。每个孩子尽可能与其父母建立关联。确定了孩子出生前后父母的临床状况。我们将儿童发热定义为在接种第一剂MCV后7至10天因发热编码而进行的门诊和急诊就诊(“MCV相关发热”)。我们使用多因素逻辑回归分析评估与MCV相关发热有关的父母临床状况。在调整了包括医疗保健利用情况等多个因素后,母亲发热(比值比[OR]=1.19,95%置信区间[CI]1.06 - 1.32)、接种MCV后发热(OR=5.90,95%CI 1.35 - 25.78)、呼吸道感染(OR=1.20,95%CI 1.10 - 1.31)、偏头痛(OR=1.14,95%CI 1.05 - 1.24)、晕厥(OR 1.14,95%CI 1.01 - 1.27)和原发性血小板增多症(OR=1.93,95%CI 1.15 - 3.25)与MCV相关发热显著相关。父亲的呼吸道感染(OR=1.15,95%CI 1.05 - 1.27)、与呼吸道感染相关的发热(OR=1.47,95%CI 1.23 - 1.76)和白癜风(OR=1.63,95%CI 1.06 - 2.53)与MCV相关发热显著相关。父母的临床状况,特别是单纯发热以及与呼吸道感染相关的发热,与孩子接种MCV后7至10天的发热有关。